Real-World Cost Savings Demonstrated by Switching Patients with Refractory Diabetic Macular Edema to Intravitreal Fluocinolone Acetonide (Iluvien): A Retrospective Cost Analysis Study.

MLA

Ch, ng, Soon W., et al. “Real-World Cost Savings Demonstrated by Switching Patients with Refractory Diabetic Macular Edema to Intravitreal Fluocinolone Acetonide (Iluvien): A Retrospective Cost Analysis Study.” Ophthalmology & Therapy, vol. 7, no. 1, June 2018, pp. 75–82. EBSCOhost, https://doi.org/10.1007/s40123-017-0114-6.

APA

Ch, ng, S. W., Brent, A. J., Empeslidis, T., Konidaris, V., & Banerjee, S. (2018). Real-World Cost Savings Demonstrated by Switching Patients with Refractory Diabetic Macular Edema to Intravitreal Fluocinolone Acetonide (Iluvien): A Retrospective Cost Analysis Study. Ophthalmology & Therapy, 7(1), 75–82. https://doi.org/10.1007/s40123-017-0114-6

Chicago

Ch, ng, Soon W., Alexander J. Brent, Theodoros Empeslidis, Vasileios Konidaris, and Somnath Banerjee. 2018. “Real-World Cost Savings Demonstrated by Switching Patients with Refractory Diabetic Macular Edema to Intravitreal Fluocinolone Acetonide (Iluvien): A Retrospective Cost Analysis Study.” Ophthalmology & Therapy 7 (1): 75–82. doi:10.1007/s40123-017-0114-6.